CAMKK2 and glioblastoma: Because CaMKK2 appears to have pro-tumor functions in human GBM, and deletion of CaMKK2 extends survival in preclinical models, we expect that a brain penetrant CaMKK2 inhibitor may be efficacious as a monotherapy.